A breakthrough study highlights Xenon gas as a potential game-changer in treating Alzheimer’s disease, demonstrating its ...
Anavex Life Sciences shares were up 7% to $11.25 after the company said it saw positive trial results for its oral blarcamesine for the treatment of early Alzheimer's disease. The clinical-stage ...
Blarcamesine potential novel oral treatment to target upstream Alzheimer’s disease pathology through autophagy enhancementImpairment of autophagy ...
Dementia, a progressive disorder that impacts memory and independence, affects millions globally. While many are aware of ...
Researchers at the University of Kentucky (UK) are part of a groundbreaking clinical trial exploring the use of medical ...
Expanded clinical practice guidelines aim to empower all clinicians, regardless of specialty or practice setting to evaluate ...